You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Adenocarcinoma, Clear Cell

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Clear Cell Carcinoma Trial (Zimberelimab, Metformin Hydrochloride)

Not yet recruiting
  • Ovarian Clear Cell Carcinoma
  • (no location specified)
Feb 25, 2023

Ovarian Clear Cell Carcinoma Trial in Houston (Dostarlimab, LB-100)

Not yet recruiting
  • Ovarian Clear Cell Carcinoma
  • Houston, Texas
    M D Anderson Cancer Center
Sep 26, 2023

Ovarian Clear Cell Carcinoma Trial (Camrelizumab)

Not yet recruiting
  • Ovarian Clear Cell Carcinoma
  • (no location specified)
Oct 29, 2022

Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma, Recurrent Renal Cell Cancer Trial

Not yet recruiting
  • Clear Cell Renal Cell Carcinoma
  • +2 more
  • (no location specified)
May 14, 2023

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Chicago, Providence (Nivolumab, Ipilimumab)

Recruiting
  • Ovarian Cancer
  • +4 more
  • Chicago, Illinois
  • +3 more
Jan 26, 2023

Ovarian Tumors, Endometrial Tumors, Uterine Cervical Tumors Trial (Dostarlimab, Bevacizumab, Doxorubicin)

Not yet recruiting
  • Ovarian Neoplasms
  • +5 more
  • (no location specified)
Sep 3, 2023

Ovarian Clear Cell Carcinoma, Gynecologic Cancer Trial in Boston (Lenvatinib, Pembrolizumab)

Recruiting
  • Ovarian Clear Cell Carcinoma
  • Gynecologic Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Oct 13, 2022

Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma, Recurrent Fallopian Tube Carcinoma Trial in Rochester (Biopsy,

Not yet recruiting
  • Fallopian Tube Carcinosarcoma
  • +14 more
  • Biopsy
  • +6 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jun 28, 2023

Advanced Solid Tumors, Solid Tumor, Solid Carcinoma Trial (Belzutifan)

Active, not recruiting
  • Advanced Solid Tumors
  • +15 more
  • (no location specified)
Sep 16, 2022

Renal Clear Cell Carcinoma, Renal Papillary Cell Carcinoma Trial in London (Savolitinib, MEDI4736, Tremelimumab)

Active, not recruiting
  • Renal Clear Cell Carcinoma
  • Renal Papillary Cell Carcinoma
  • London, United Kingdom
    Thomas Powles
Aug 10, 2022

Advanced Solid Tumor, Advanced Cancer, Advanced Carcinoma Trial (AMT-151)

Not yet recruiting
  • Advanced Solid Tumor
  • +18 more
  • (no location specified)
Aug 10, 2022

Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid

Not yet recruiting
  • Recurrent Endometrial Carcinoma
  • +8 more
  • BET Bromodomain Inhibitor ZEN-3694
  • +7 more
  • (no location specified)
Jul 15, 2023

Stage I Testicular Seminoma, Stage I Testicular Nonseminomatous Germ Cell Tumor, Gastrointestinal Stromal Tumors Trial in

Not yet recruiting
  • Stage I Testicular Seminoma
  • +13 more
  • Oncological Follow-up
  • Amiens, France
  • +2 more
Aug 12, 2022

Ovarian Cancer, Fallopian Tube Adenocarcinoma, Fallopian Tube Carcinosarcoma Trial in Seattle (Exercise Counseling, Aerobic

Terminated
  • Ovarian Cancer
  • +21 more
  • Exercise Counseling
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 6, 2022

Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer Trial in New Haven (APG-5918)

Recruiting
  • Nasopharyngeal Carcinoma
  • +8 more
  • Springdale, Arkansas
    Highlands Oncology
Nov 11, 2022

Clinicopathologic and Ancillary Testing of Primary Clear Cell

Recruiting
  • Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type
  • Electronic Health Record Review
  • Laboratory Biomarker Analysis
  • Houston, Texas
    M D Anderson Cancer Center
Sep 13, 2021

Liquid Biopsies and Tumor Molecular Profiling in Predicting

Recruiting
  • Endometrial Clear Cell Adenocarcinoma
  • +5 more
  • Biospecimen Collection
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 3, 2022

Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Tumor Trial in Rochester

Active, not recruiting
  • Fallopian Tube Clear Cell Adenocarcinoma
  • +22 more
  • Laboratory Biomarker Analysis
  • Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
  • Rochester, Minnesota
    Mayo Clinic
Oct 7, 2022

Adenocarcinomas, Recurrent Gynecological Trial in Singapore (pembrolizumab and lenvatinib)

Recruiting
  • Adenocarcinomas
  • Recurrent Gynecological
  • pembrolizumab and lenvatinib
  • Singapore, Singapore
    National University Hospital
Oct 13, 2021

Kidney Cancer, Renal Cell Carcinoma, Clear Cell Carcinoma Trial in Dallas (13C-Glucose, 13C-Acetate, 13C-Lactate)

Recruiting
  • Kidney Cancer
  • +11 more
  • 13C-Glucose
  • +4 more
  • Dallas, Texas
    University of Texas Southwestern Medical Center
Dec 1, 2022

Ovarian Clear Cell Carcinoma Trial in Wuhan (Sintilimab, Bevacizumab Biosimilar IBI305)

Recruiting
  • Ovarian Clear Cell Carcinoma
  • Wuhan, Hubei, China
    Tongji Hospital of Tongji Medical College, Huazhong University o
Apr 18, 2022

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial (3 cycles chemo instead of 6 cycles chemo, 6 cycles

Not yet recruiting
  • Ovarian Cancer
  • +3 more
  • 3 cycles chemotherapy instead of 6 cycles chemotherapy
  • 6 cycles chemotherapy
  • (no location specified)
Jul 12, 2022

Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Platinum-Resistant

Recruiting
  • Recurrent Fallopian Tube Clear Cell Adenocarcinoma
  • +5 more
  • Etigilimab
  • Nivolumab
  • Houston, Texas
    M D Anderson Cancer Center
Nov 22, 2021

Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma Trial in United States (biological, other,

Recruiting
  • Cervical Adenocarcinoma
  • +47 more
  • Bevacizumab
  • +3 more
  • Phoenix, Arizona
  • +3 more
Dec 5, 2022

Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma Trial in

Recruiting
  • Recurrent Endometrial Adenocarcinoma
  • +8 more
  • Ipilimumab
  • Nivolumab
  • Iowa City, Iowa
  • +9 more
Jan 27, 2023